

CPT® Category I New Immunization* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

Most recent changes to the CPT® Category I New Immunization* Vaccine Codes Long Descriptor document:

- There are no changes to report for the October 2025 Immunization Vaccine codes early release.

*For the purposes of CPT coding, "Immunization" includes vaccines/toxoids, immune globulins, serum or recombinant products.

It is important to note that further CPT Editorial Panel or Executive Committee actions may affect these codes and/or descriptors. For this reason, code numbers and/or descriptor language in the CPT code set may differ at the time of publication. In addition, further Panel actions may result in gaps in code number sequencing.

The following vaccine code was accepted at the September 2024 CPT Editorial Panel meeting for the 2026 CPT production cycle. This code is effective on January 1, 2025, following the three-month implementation period which begins October 18, 2024. FDA approval was received on February 14, 2025.

*Note that code 90593 will follow code 90589.

Codes	Long Descriptor	Released to AMA Website	Effective	Publication
#●90593	Chikungunya virus vaccine, recombinant, for intramuscular use	October 18, 2024	January 1, 2025	CPT® 2026

The following immunization codes were accepted at the February 2025 CPT Editorial Panel meeting for the 2026 CPT production cycle. These codes are effective on July 1, 2025, following the three-month implementation period which begins April 1, 2025. FDA approval was received for code 91323 on May 30, 2025, and for code 90382 on June 9, 2025.

*Note that code 91323 will follow code 91322, code 90635 will follow code 90668, codes 90612 and 90613 will follow code 90638, and code 90620 will follow code 90624.

Codes	Long Descriptor	Released to AMA Website	Effective	Publication
#●90382	Respiratory syncytial virus, monoclonal antibody, seasonal dose, 0.7 mL, for intramuscular use	April 1, 2025	July 1, 2025	CPT® 2026
#●91323	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 10 mcg/0.2 mL dosage, for intramuscular use	April 1, 2025	July 1, 2025	CPT® 2026
#●90635	Influenza virus vaccine, H5N1, derived from cell cultures, adjuvanted, for intramuscular use	April 1, 2025	July 1, 2025	CPT® 2026
#●90612	Influenza virus vaccine, trivalent, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 31.7 mcg/0.32 mL dosage, for intramuscular use	April 1, 2025	July 1, 2025	CPT® 2026

CPT® Category I New Immunization* Vaccine Codes (Including Incorporation of ACIP Abbreviations Listing) Long Descriptors

#●90613	Influenza virus vaccine, quadrivalent, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 40 mcg/0.4 mL dosage, for intramuscular use	April 1, 2025	July 1, 2025	CPT® 2026
#▲90620	Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), 2-dose schedule , for intramuscular use	April 1, 2025	July 1, 2025	CPT® 2026

The following vaccine code was accepted at the May 2025 CPT Editorial Panel meeting for the 2026 CPT production cycle. This code will be effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration.

***Note that code 90631 will follow code 90668.**

Codes	Long Descriptor	Released to AMA Website	Effective	Publication
#●90631	Influenza virus vaccine (IIV), H5, pandemic formulation, split virus, adjuvanted, for intramuscular use	May 9, 2025	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT® 2026

The removal of the FDA pending symbol follows notification that this product has been granted FDA approval status on the date indicated. Code 90671 was originally published in CPT 2022.

Codes	Long Descriptor	Released to AMA Website	FDA Approval Effective	Publication
★90671	Pneumococcal conjugate vaccine, 15 valent (PCV15), for intramuscular use	June 16, 2025	July 16, 2021	CPT® 2026